Table 4.

Association of N¹-MN excretion with risk of all-cause mortality in RTR ¹.

Model	N1-MN Excretion (log2) As Continuous Variable n = 660		Tertiles of Sex-Stratified N1-MN Excretion 2
			T1 n = 219		T2 n = 221		T3 n = 220
	HR (95% CI)	p-Value	HR (95% CI)	p-Value	HR (95% CI)	p-Value	Reference HR
1 3	0.53 (0.43–0.65)	<0.001	3.28 (2.04–5.26)	<0.001	2.41 (1.48–3.93)	<0.001	1.00
2 4	0.57 (0.45–0.71)	<0.001	2.68 (1.67–4.33)	<0.001	2.04 (1.25–3.34)	0.004	1.00
3 5	0.59 (0.47–0.74)	<0.001	2.65 (1.60–4.39)	<0.001	2.10 (1.25–3.52)	0.005	1.00
4 6	0.69 (0.53–0.90)	0.005	2.10 (1.17–3.78)	0.01	2.04 (1.15–3.63	0.02	1.00
5 7	0.75 (0.58–0.96)	0.02	1.86 (1.07–3.25)	0.02	1.80 (1.04–3.13)	0.04	1.00
6 8	0.65 (0.51–0.82)	<0.001	2.25 (1.35–3.75)	0.002	2.06 (1.23–3.46)	0.006	1.00
7 9	0.60 (0.48–0.76)	<0.001	2.59 (1.54–4.35)	<0.001	2.13 (1.26–3.61)	0.005	1.00
Events (n)	143		67		53		23

¹ Cox regression analyses were performed to investigate the association of N¹-MN excretion with risk of all-cause mortality in RTR, with adjustment for potential confounders. ² N¹-MN excretion was <19.2, 19. 2–28.8, and >28.8 μmol/day for males, and <16.1, 16.1–25.6, and >25.6 μmol/day for females in T1, T2, and T3, respectively. ³ Model 1: not adjusted in tertiles of sex-stratified N¹-MN excretion, adjusted for sex in continuous analyses. ⁴ Model 2: adjusted as for model 1 and for age. ⁵ Model 3: adjusted as for model 2 and for smoking and body surface area. ⁶ Model 4: adjusted as for model 3 and for intake of alcohol and energy and plasma vitamin B₆. ⁷ Model 5: adjusted as for model 3 and for eGFR, proteinuria, donor status and primary glomerular disease. ⁸ Model 6: adjusted as for model 3 and for use of proliferation inhibitors, acetylsalicylic acid, proton pump inhibitors and diuretics. ⁹ Model 7: adjusted as for model 3 and for hs-CRP. eGFR, estimated glomerular filtration rate; hs-CRP, high-sensitivity C-reactive protein; N¹-MN, N¹-methylnicotinamide; RTR, renal transplant recipients.